An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

Inclusion Criteria: * Adults patients \>= 18 years of age * Patients with histologically confirmed metastatic melanoma (surgically incurable and unresectable stage IIIC or stage IV; AJCC) with documented BRAF V600 mutation determined by the cobas® BRAF V600 Mutation Test prior to administration of vemurafenib. Unresectable stage IIIC disease must have confirmation from a surgical oncologist * Patients with either measurable or non-measurable disease (RECIST Version 1.1) * Patients may or may not have received prior systemic therapy for metastatic melanoma * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 * Patients must have recovered from all side effects of their most recent systemic or local treatment for metastatic melanoma * Adequate hematological, renal, and liver function * Negative serum pregnancy test at screening * Fertile men and women must use an effective form of contraception during the study and for at least 6 months after completion of the study Exclusion Criteria: * Evidence of symptomatic CNS lesions as determined by the investigator, use of steroid or anti-seizure medication for treatment of brain metastases prior to the first administration of vemurafenib * Patients with previous malignancies (other than melanoma) within the past 2 years except patients with treated and controlled basal or squamous cell carcinoma (SCC) of the skin or carcinoma in-situ of the cervix. * Concurrent administration of any anti-cancer therapies (e.g.…